ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Hormonal functional status and prognostic stratification in adrenocortical carcinoma: a single-center retrospective cohort study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdrenocortical carcinoma (ACC) is a rare and aggressive malignancy in which cortisol secretion has been associated with poor survival. However, whether this adverse prognosis reflects intrinsically more aggressive tumor biology or merely established pathological predictors remains uncertain.
methodsWe conducted a single-center retrospective cohort of adults with histologically confirmed ACC. Tumors were classified by functional status. Aggressive pathology (Ki-67 ≥ 20%, mitotic rate ≥ 20/50 HPF, or R1/R2 margins) was compared across subgroups, and survival was analyzed using Kaplan-Meier methods.
resultsThirty-nine patients were included. Cortisol-secreting tumors exhibited higher Ki-67 and mitotic rates, a greater frequency of incomplete resection, and higher use of adjuvant mitotane compared with non-functioning and androgen-secreting ACC. These differences persisted when analyses were restricted to advanced ENSAT stage (III-IV). Cortisol secretion was strongly associated with fulfillment of the composite aggressive pathology endpoint and identified discordant cases with low ENSAT stage but adverse pathological features. Increasing pathological aggressiveness across functional subgroups was confirmed by trend analyses. Overall survival differed by functional status, with the worst outcomes in cortisol-secreting ACC, even after adjustment for age and sex. Importantly, cortisol secretion further stratified prognosis among tumors with Ki-67 ≥ 20%, indicating adverse prognostic information beyond proliferative activity alone.
conclusionsCortisol-secreting ACC is associated with a distinct and more aggressive pathological and clinical phenotype. Hormonal functional status provides prognostic information beyond ENSAT stage and proliferative indices, supporting its integration into contemporary risk stratification frameworks.
Indexed as
Identifiers
42207431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.